Kronos Bio (KRON)
(Real Time Quote from BATS)
$0.82 USD
+0.06 (8.51%)
Updated May 28, 2024 10:06 AM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KRON 0.82 +0.06(8.51%)
Will KRON be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for KRON based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KRON
Down -5.63% in 4 Weeks, Here's Why Kronos Bio (KRON) Looks Ripe for a Turnaround
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates
KRON: What are Zacks experts saying now?
Zacks Private Portfolio Services
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates
Other News for KRON
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial OfficerÂ
Kronos Bio appoints Knobelman as CFO and COO